Amylyx Pharmaceuticalsの空売り状況は、投資家がAmylyx Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Amylyx Pharmaceuticals (NASDAQ:AMLX) 株価情報, 空売り情報

AMYLYX PHARMACEUTICALS INC

Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals Inc

Mark Rutte, the NATO Secretary-General, has extended his appreciation to President Donald Trump for his significant contribution to the escalation of European defense spending.
What Happened:&nbsp;&nbsp;Rutte&#8217;s message to Trump, which was shared on the president&#8217;s social media platform, Truth Social, commended Trump for driving Europe to a pivotal point in terms of defense spending. Rutte acknowledged Trump&#8217;s demand for all NATO allies to raise defense spending to 5% of their GDP, a move that has been met with controversy, particularly from Spain.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25071906/Screenshot-2025-06-25-at-4.48.54%E2%80%AFPM-638x1024.png" alt="" class="wp-image-961437" /></figure>
"It was not easy but we've got them all signed onto 5 per cent!" Rutte wrote. "Europe is going to pay in a BIG way, as they should, and it will be your win."
Despite the ongoing dispute, Rutte congratulated Trump for getting all allies, except Spain, to commit to the 5% target. This praise comes in the wake of Trump&#8217;s criticism of Spain&#8217;s opposition to the 5% demand, which he labeled as &#8220;very unfair to the rest&nbsp;of the people&#8221; while talking to reporters on Air Force One on his way to NATO. 
However, Spain&#8217;s reluctance to commit to the 5% target has stirred up controversy and heightened&nbsp;the likelihood of a clash&nbsp;at the forthcoming NATO summit. Despite this, Rutte reassured allies that Trump would not retract U.S. guarantees as long as they significantly ramped up their defense spending, <a href="https://www.ft.com/content/ce9eb7e4-7989-45f6-a3b3-3cdec73a8540">reported </a>The Financial Times. 
To address Trump's demands, Rutte has put forward a plan for allies to dedicate 3.5% of their GDP to core military spending and an additional 1.5% to areas like cyber capabilities and infrastructure by 2035.
See Also:&nbsp;<a href="https://benzinga.com/pressreleases/24/10/ab41310379/claritycheck-launches-innovative-reverse-lookup-tool-to-empower-users-against-digital-scams" target="_blank" rel="noreferrer noopener">ClarityCheck Launches Innovative Reverse Lookup Tool to Empower Users Against Digital Scams &#8211; Benzinga</a>
Why It Matters: The push for increased defense spending in Europe comes at a time when global defense budgets have reached unprecedented levels. According to a report by the&nbsp;Stockholm International Peace Research Institute (SIPRI), <a href="https://www.benzinga.com/25/04/45032800/global-defense-budgets-surge-to-27-trillion-as-europe-and-middle-east-lead-steepest-increase-since-cold-war-report">military expenditure </a>rose by 9.4% to $2.72 trillion in 2024, marking the most significant annual increase since the Cold War.
This demand for increased defense spending has also led to diplomatic tensions, as seen in the recent cancellation of a key security summit between the U.S. and Japan. Tokyo canceled the meeting after the Trump administration raised its demand for Japan to increase defense spending to 3.5% of GDP, up from the previously requested 3%.
Despite the controversy, NATO is actively seeking partnerships with the private sector to develop emerging and disruptive technologies, such as AI systems, to maintain its technological dominance over its adversaries.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/politics/25/06/46087132/elizabeth-warren-says-the-tax-break-for-mark-zuckerbergs-meta-is-so-bountiful-under-trumps-big-beau" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says The Tax Break For Mark Zuckerberg&#8217;s Meta Is So Bountiful Under Trump&#8217;s &#8216;Big Beautiful Bill&#8217; That $35 Copay From Each American Won&#8217;t Still Match I</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

Trump Made 'Europe…Pay In A Big Way:' NATO Chief Lauds Role In Boosting Defense Spending

Superior Industries International, Inc. ("Superior" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>), one of the world's leading aluminum wheel suppliers, today announced that on June 24, 2025, it received a written notice from the New York Stock Exchange (the "NYSE") that the NYSE had determined to (A) immediately suspend trading in the Company's common stock, par value $0.01 per share (the "Common Stock"), due to a determination that the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Common Stock.
The NYSE stated that it will apply to the Securities and Exchange Commission (the "SEC") to delist the Common Stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE's delisting determination. The Company does not intend to appeal the delisting determination.
Upon suspension of the trading of the Common Stock on NYSE, the Company expects that the Common Stock will trade publicly on the Pink Open Market operated by the OTC Markets Group, Inc. (commonly referred to as the "pink sheets") under the ticker symbol "SSUP" beginning on June 25, 2025.

Superior Industries Receives NYSE Delisting Notice After Market Cap Falls Below Threshold

QS: 42% &#x7C; <a href="https://www.benzinga.com//node/46083645">QuantumScape Achieves Key 2025 Milestone In The Scale-Up Of Its Production Capabilities With The Successful Integration Of Its Advanced Cobra Separator Process Into Baseline Cell Production</a>
&nbsp;
DTIL: 22% &#x7C; <a href="https://www.benzinga.com//node/46091286">Precision BioSciences shares are trading higher after the company received FDA Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy.</a>
&nbsp;
FDX: -6% &#x7C; <a href="https://www.benzinga.com//node/46082829">FedEx shares are trading lower after the company reported Q4 financial results.</a>

Movers

Trading Ideas

DTIL

Market-Moving News for June 25th

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fsprout.ai&amp;esheet=54280379&amp;newsitemid=20250624877897&amp;lan=en-US&amp;anchor=Sprout.ai&amp;index=1&amp;md5=c8273fb12f0f87e48620c05c08fc1095">Sprout.ai</a>, an insurance automation specialist, today announced it has partnered with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.metlife.com%2F&amp;esheet=54280379&amp;newsitemid=20250624877897&amp;lan=en-US&amp;anchor=MetLife&amp;index=2&amp;md5=ebddc9fca359e0248ce5de25eb68da34">MetLife</a>, a leading global insurer, to drive claims automation and deliver improved claims experiences. The collaboration, which spans multiple territories across the US, Asia and LATAM regions, is aimed at improving accuracy, speed and the overall customer experience.
 &nbsp;

Sprout.ai Partners With MetLife To Drive Claims Automation And Deliver Improved Claims Experiences

ACIW

ACI Worldwide's Craig Ramsey Elected To US Faster Payments Council Board Of Directors To Help Advance Real-Time Payments

Commodities

Markets

IAMGOLD Completes Final Delivery OF Gold Ounces As Required Under Gold Prepay Arrangements

Idaho Strategic Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDR#NYSE">IDR</a>) ("IDR" or the "Company") is pleased to share an update on exploration and development activities across its extensive portfolio of precious metals and critical minerals projects.
John Swallow, President and CEO of Idaho Strategic Resources commented, "With our annual meeting this Monday, increased activity around the Russell reconstitution, and production moving as expected- by almost any measure the breadth of activity underway at IDR is impressive. We have spent many years building the gold production side of the Company's business plan while also building an asset base, strong balance sheet and share structure to not only capitalize on today but have the flexibility to strategically position for what comes next. With the help of solid gold grades, a strong gold price and being a producing gold company, IDR finds itself in a position to invest in the exploration side of its business plan like never before. For the first time ever, we are testing drill targets and advancing exploration plans across the entirety of our extensive property portfolio. Below is an overview of our multi-tiered exploration and development activities thus far in 2025:"
Precious Metals
Golden Chest Mine: The Golden Chest continues to be the busiest of the Company's assets. In addition to production as usual, 2025 has seen a significant increase in the amount of exploration and development work on-site. On the development front, the Company is continuing with the buildout of the paste backfill system and its plans for the new Murray Mill (Figures 1 &amp; 2). The second quarter saw the completion of four bore holes drilled from the surface into the existing underground infrastructure to facilitate the eventual pumping of paste underground for backfilling stopes, additional equipment purchases were made as a part of the Company's Murray Mill plans, and construction began on a new storage building located between the Company's existing core shed and the mechanic's shop (Figures 3 &amp; 4). Additionally, late in the second quarter, Small Mines Development ("SMD") was mobilized to develop two underground drill stations in the northern part of the Golden Chest Mine. The two drill stations are necessary for better drilling orientations of the Red Star area and targeting multiple known veins in the footwall of the Idaho Fault, such as the Claggett and Popcorn veins.
On the exploration front, there are currently two drill rigs turning at the Golden Chest Mine, one underground and one on the surface. The drill rig underground is primarily drilling infill targets on the H-Vein north and updip of the current underground workings (Figure 5). The timeline for this infill drill program is coinciding with the development timeline for the two additional underground drill stations being developed by SMD, which should allow for a seamless move to those stations upon completion. The surface drill rig at the Golden Chest was mobilized to the site in mid-June and is following up on promising drill results from the Paymaster Footwall Vein. The planned program is designed to test the Paymaster Vein downdip from the current resource and will consist of approximately 9 holes for 3,000 total meters (Figure 6).
Murray Gold Belt: Surface drilling in the Murray Gold Belt began at the start of June. The drilling planned in the Murray Gold Belt this summer is designed to provide a 1st phase drill test of various prospects throughout the district. IDR's geologists have had drill programs in mind for many of these prospects for years, and only just now has the Company had the cash flow and resources to put those plans into action. Drilling throughout the Murray Gold Belt is expected to continue throughout the summer with at least 5 different prospects being tested. Thus far, 7 holes have been completed at the Company's Buckskin prospect. The drill program outlined at the Buckskin prospect is targeting a large fault structure and its associated gold-bearing veins; identified by historic adits, trenching, and magnetics (Figure 7). Following a sufficient 1st phase test of the Buckskin prospect, the drill rig will be moved to the King Mine prospect to test a set of parallel gold-bearing quartz veins referenced in historic literature and seen in surface work conducted by IDR (see Figure 8 for an overview of approximate prospect locations within the Murray Gold Belt).
Eastern Star: Idaho Strategic completed a 1st phase drill program at its Eastern Star project located near Elk City, Idaho during the months of April and May this year. The 1st phase drill program was designed to test areas beneath a surface trenching program that yielded positive results in 2014. The recently completed drill program totaled 13 holes for 1,965 meters and tested various targets from three different locations across the property. IDR specifically targeted narrow vein, high-grade underground structures rather than lower-grade, bulk minable mineralization commonly targeted at nearby projects within the Orogrande Shear Zone. While there were challenges faced throughout the program, including clay alteration and tough drilling in certain areas as well as difficult weather conditions, the Company believes that the program was ultimately successful, and a visual review of the drill core shows some promising intercepts. IDR geologists are looking forward to receiving the final multi-element assay results from ALS Chemex later in the summer.
Critical Minerals
Mineral Hill: During the second quarter, IDR completed its planned LiDAR and magnetics geophysical drone survey on its extensive landholdings in the Mineral Hill area and scheduled a follow-on radiometrics drone survey to be completed next month. While the results of the comprehensive dataset have not yet been received, the Company is extremely encouraged by the magnetics "bullseye" data viewed to date. Due to the presence of magnetite within the carbonatites at Mineral Hill, the magnetics survey picked up the known rare earth bearing carbonatites well and identified additional areas of similar magnetics readings within the Company's project boundary that have yet to be visited by IDR's geologists, making for additional high priority exploration targets during the remainder of 2025 (see also Lemhi Pass plans below).
Lemhi Pass: The planned widespread soil sampling (approx. 2,000 samples) and ground-based radiometrics program at Lemhi Pass is well underway by an experienced crew of contractors. This phase of work is targeting high-potential prospects where known rare earth elements mineralization occurs. Additionally, after seeing the effectiveness of the magnetics program at Mineral Hill, the Company has decided to contract the same - yet considerably larger - survey at Lemhi Pass to compliment the current work planned for the summer. The geophysical work completed at both Mineral Hill and Lemhi Pass will aid immensely as IDR plans for future drilling at both projects as the next phase of its rare earth exploration plans.
Diamond Creek: IDR's Diamond Creek project is currently planned to be advanced through an initial trenching program at both the Simer and Frank Burch prospects, with possible drilling late in the season pending successful trenching results. Simer and Frank Burch are two prospects on-strike from Diamond Creek's Lucky Gem and Contact prospects, which were successfully trenched and drilled in 2022. In addition to drilling and trenching yielding wide intercepts exceeding 1% total rare earths, the presence of niobium and elevated levels of yttrium make Diamond Creek a compelling critical minerals target for follow-up exploration work during 2025.
Additional Projects
Oxford: Idaho Strategic added the Oxford copper project to its mineral portfolio in 2024. The Oxford project is located near the town of Pierce, Idaho approximately 3.5 hours south of the Company's headquarters in Coeur d'Alene, Idaho. The Oxford project consists of approximately 3,000 total acres, made up of a combination of state mineral lease land and unpatented mining claims. While the Oxford project is extremely underexplored and lacks substantial geologic data, IDR's geologists believe it to be a compelling exploration stage project with the target being a potential buried copper porphyry. Similar copper porphyry targets have recently been discovered in Idaho and share some of the characteristics expressed by the Company's Oxford project to date. Thus far, IDR has carried out multiple soil sampling programs showing anomalous copper-in-soil results and revealing high-grade grab samples near the collapsed shaft of the historic Oxford copper mine- a small underground copper mine located on the property with limited historic data available. Idaho Strategic's plan to further test its hypothesis for a potential buried copper porphyry is to complete a 3D IP geophysics survey to test the chargeability and resistivity of the rock deep beneath the surface. All necessary approvals from the state have been received and the contractor is scheduled to complete the planned work this summer. The results of the 3D IP geophysics survey will likely determine the next steps in the exploration of this project.

Idaho Strategic Ramps Up Gold and Rare Earth Exploration Across Multiple Sites With Summer Drilling in Full Swing

GILD

KYMR

Gilead Sciences And Kymera Enter Into Exclusive Option And License Agreement To Accelerate Development And Commercialization Of MGD Program Targeting CDK2 With Broad Oncology Treatment Potential Including In Breast Cancer And Other Solid Tumors

Financing

Metalla Royalty & Streaming Announces Up To $75M Revolving Credit Facility

<a href="https://www.bloomberg.com/news/articles/2025-06-25/tsmc-unit-to-issue-10-billion-of-stock-to-counter-forex-swings" title="https://www.bloomberg.com/news/articles/2025-06-25/tsmc-unit-to-issue-10-billion-of-stock-to-counter-forex-swings">https://www.bloomberg.com/news/articles/2025-06-25/tsmc-unit-to-issue-10-billion-of-stock-to-counter-forex-swings</a>

Offerings

Bloomberg Reported TSMC Unit to Issue $10B Of Stock To Counter Forex Swings

Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474
In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile
Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties, and may opt-in to 50/50 development and profit share of KT-485 in the U.S.
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=AyHITazssJoCxpat9kb5fz0WQ159VdrhYyAiX-UZp4uAZ4dmW7fXI00uSg-8aKmdw0UeYpGXvl4OgG0aKqE4ppd3o-Jhswd5xKNi6IWiGRY=">Kymera Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced an update to its IRAK4 partnership with Sanofi.
Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance into clinical studies. Following extensive preclinical work supporting its robust development potential, KT-485 is being prioritized for development under the companies' existing IRAK4 collaboration, and is expected to advance into Phase 1 testing next year. Based on the planned development of KT-485, Sanofi will not advance KT-474.
In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the terms of the companies' collaboration agreement. Under the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485. Kymera is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.

Sanofi To Advance Kymera's Next-Generation Oral IRAK4 Degrader Development Candidate, KT-485, Into Clinical Testing And Will Not Advance KT-474

AQST

Aquestive To Showcase Anaphylm Sublingual Film Stability And Clinical Efficacy At Upcoming CFAAR Food Allergy Summit In Chicago

Biotech

Health Care

General

PRTG

Portage Biotech Received Formal Notice With All Applicable Requirements For Continued Listing On The Nasdaq Capital Market

IONQ

IonQ And University Of Washington Announce Simulation Using A Quantum Computer Of A Process Called 'neutrinoless double-beta decay'

ALMU

Aeluma, Added To Russell 3000 Index, Effective June 30, As Part Of 2025 Russell Indexes Reconstitution

Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) lowers FY2025 Adj EPS guidance from $2.75-$3.75 to $1.20-$1.70 vs $1.74 analyst estimate. Lowers FY2025 sales outlook from $2.800 billion-$3.000 billion to $2.700 billion-$2.800 billion vs $2.758 billion estimate.

Guidance

Winnebago Industries Lowers FY2025 Adj EPS Guidance from $2.75-$3.75 to $1.20-$1.70 vs $1.74 Est; Lowers FY2025 Sales Guidance from $2.800B-$3.000B to $2.700B-$2.800B vs $2.758B Est

The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>), the nation's largest franchisor of chiropractic care through The Joint Chiropractic&#xAE; network, has signed a binding Asset Purchase Agreement (APA) for the sale of 31 corporate owned and managed clinics in Arizona and New Mexico to Joint Ventures, LLC in exchange for cash and the regional developer (RD) territory rights of the Northwest region. The sale is expected to close on or before June 30, 2025. In addition, the company refranchised five clinics to Chiro 93, LLC in the Kansas City region.
<ul>
<li>Joint Ventures, The Joint's largest franchisee, will acquire 31 clinics, increasing its clinic count to 96 clinics located throughout California, Oregon, New Mexico, and Arizona, and agreed to open another 10 clinics in this same region.</li>
<li>The Joint to acquire the regional developer rights to the Northwest region, consisting of 46 existing franchised clinics and 30 sites for future clinic development.</li>
<li>The Joint sold the five clinics along with future development rights in the Kansas City region to Chiro 93, led by existing franchisee Dr. Clint Morrow, D.C. &nbsp;</li>
</ul>
Joint Ventures franchisee, Chris O'Neal stated, "We are proud to be the largest franchise group at The Joint and plan to increase our ownership by more than 50% to over 100 clinics when we complete our expansion. When run correctly, the clinics provide excellent patient care, conduct compelling marketing campaigns growing the patient base and deliver strong operating metrics. We support Sanjiv's growth plan and are excited to expand our position and earnings potential with The Joint."
The Joint Corp.'s President, Chief Executive Officer and Director, Sanjiv Razdan said, "Chris is a strong operator, and we are delighted to augment our partnership with Joint Ventures. Their large investment demonstrates confidence in our business model. This significant validation is compounded by additional franchisees' interest in our entire corporate portfolio.

JYNT

The Joint Sells 31 Clinics to Largest Franchisee, Expands Northwest Territory Ahead of June 30 Deal Close

AGF Management (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AGF#TSX">AGF</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.41 by 17.07 percent. This is a 5.88 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $111.50 million which missed the analyst consensus estimate of $141.65 million by 21.28 percent. This is a 8.25 percent increase over sales of $103.00 million the same period last year.

Earnings

TSX:AGF

TSX:AGF.B

AGF Management Q1 EPS $0.48 Beats $0.41 Estimate, Sales $111.50M Miss $141.65M Estimate

Global Transformation Initiative&nbsp; In the fourth quarter of fiscal 2025, General Mills announced a multi-year global transformation initiative aligned with its Accelerate strategy and designed to accelerate growth. The initiative is focused on streamlining end-to-end business processes and identifying new ways of working that match today's evolving business environment, using new tools, technologies, and operating models to enable greater agility. By optimizing how work gets done, General Mills will be able to invest more resources in driving growth. The company expects the global transformation initiative and additional efficiency efforts to generate $100 million in incremental cost savings in fiscal 2026.

In Q4 2025, General Mills Announced A Multi-year Global Transformation Initiative That Is Expected To Generate $100M In Incremental Cost Savings In Fiscal 2026

LASE

Laser Photonics Regains Compliance With Nasdaq Over Annual Filing Requirement

Press Releases

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Legal

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Comments

Amylyx Pharmaceuticals

空売り

Amylyx Pharmaceuticals (NASDAQ:AMLX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル